Development andin vitro characterization of vascular endothelial growth factor (VEGF)-loaded poly(DL-lactic-co-glycolic acid)/poly(ethylene glycol) microspheres using a solid encapsulation/single emulsion/solvent extraction technique
- 5 September 2000
- journal article
- research article
- Published by Wiley in Journal of Biomedical Materials Research
- Vol. 51 (3) , 383-390
- https://doi.org/10.1002/1097-4636(20000905)51:3<383::aid-jbm12>3.0.co;2-d
Abstract
Poly(DL-lactide-co-glycolide) (PLGA)/polyethylene glycol (PEG) microspheres are one modality of controlled delivery of biologically active molecules that would further the development of engineered tissues. As a possible mechanism to stimulate angiogenesis within an engineered tissue, vascular endothelial growth factor (VEGF) and bovine serum albumin (BSA) were coencapsulated into microspheres fabricated from PEG and 50/50 PLGA using a solid-encapsulation/single-emulsion/solvent extraction technique. Two VEGF/BSA ratios were studied: 1:2000 and 1:10,000. Analysis consisted of the loading efficiency, particle size distribution, bright-field microscopy, scanning electron microscopy, release kinetics, and an in vitro human umbilical vein endothelial cell proliferation assay to assess biological activity of the released VEGF. Results show the microspheres could be manufactured, stored, and degraded over 28 days. The burst release rates for 1:2000 and 1:10,000 VEGF/BSA microspheres were 71.87 ± 8.11 and 27.91 ± 1.71 ng/mL (mean ± standard error of the mean), respectively; steady-state release rates were 6.56 ± 1.10 and 2.21 ± 0.47 ng/mL, respectively. The microspheres released biologically active VEGF, and the VEGF increased the proliferation of HUVECs in culture (p < .05). The successful development of a novel, cost-effective, scalable technique for producing microspheres loaded with biologically active proteins is presented. Using the data obtained from these studies, a defined concentration of microspheres will deliver a quantifiable level of VEGF at a known release rate. © 2000 John Wiley & Sons, Inc. J Biomed Mater Res, 51, 383–390, 2000.Keywords
This publication has 31 references indexed in Scilit:
- Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cellsPublished by Elsevier ,2004
- Delivering neuroactive molecules from biodegradable microspheres for application in central nervous system disordersBiomaterials, 1999
- Inhibition of smooth muscle cell growthin vitro by an antisense oligodeoxynucleotide released from poly(DL-lactic-co-glycolic acid) microparticlesJournal of Biomedical Materials Research, 1997
- Synergistic Effect of Vascular Endothelial Growth Factor and Basic Fibroblast Growth Factor on Angiogenesis In VivoCirculation, 1995
- Recovery of Disturbed Endothelium-Dependent Flow in the Collateral-Perfused Rabbit Ischemic Hindlimb After Administration of Vascular Endothelial Growth FactorCirculation, 1995
- Site-specific therapeutic angiogenesis after systemic administration of vascular endothelial growth factorJournal of Vascular Surgery, 1995
- Angiogenic-induced enhancement of collateral blood flow to ischemic myocardium by vascular endothelial growth factor in dogs.Circulation, 1994
- Therapeutic angiogenesis. A single intraarterial bolus of vascular endothelial growth factor augments revascularization in a rabbit ischemic hind limb model.Journal of Clinical Investigation, 1994
- Angiogenesis.Journal of Biological Chemistry, 1992
- Isolation and characterization of a vascular endothelial cell mitogen produced by pituitary-derived folliculo stellate cells.Proceedings of the National Academy of Sciences, 1989